



Cancer Prevention and Control CIRB Meeting Agenda

December 28, 2023

I. Initial Review

INT23-14-01, Refining Tamoxifen Dose for Premenopausal Breast Cancer Risk Reduction (RENAISSANCE): A Phase II Single Arm Trial (Version Date 11/20/23)

II. Initial Review

WF-2302, A Randomized, Placebo-Controlled, Pilot Study of Lactoferrin for Taste and Smell Disturbances in Cancer Patients Receiving Therapy (TASTE) (Version Date 10/10/23)

III. Amendment

A211801, BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to Determine the Preventive Effect of Denosumab on Breast Cancer in Women Carrying a BRCA1 Germline Mutation (Version Date 10/26/23)

IV. Amendment

S1703, Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer (Version Date 11/02/23)

V. Amendment

A221805, Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study (Version Date 11/14/23)

VI. Amendment

UWI20-00-01, A Phase II Trial of the Immunogenicity of a DNA Plasmid Based Vaccine (STEMVAC) Encoding Th1 Selective Epitopes from Five Antigens Associated With Breast Cancer Stem Cells (MDM2, YB1, SOX2, CDH3, CD105) in Participants with Triple Negative Breast Cancer (Version Date 12/07/23)

VII. Continuing Review

A222004, A Randomized Phase III Trial Of Olanzapine Versus Megestrol Acetate For Cancer-Associated Anorexia (Version Date 07/21/23)

VIII. Continuing Review

EA1151, Tomosynthesis Mammographic Imaging Screening Trial (TMIST) (Version Date 10/05/23)

IX. Continuing Review

EA2185, Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs (Version Date 05/25/23)

X. Continuing Review

NWU20-01-03, Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD): RELIEF-NAFLD (Version Date 12/20/22)

XI. Continuing Review

URCC-16070, Treatment of Refractory Nausea (Version Date 01/04/23)

XII. Continuing Review

URCC-19178, Optimizing Functional Outcomes of Older Cancer Survivors After Chemotherapy The GEM-S Study (Version Date 02/09/23)
